Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VYNE Therapeutics Inc.    VYNE

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

VYNE Therapeutics to Report Third Quarter 2020 Financial Results on November 5th

10/28/2020 | 07:00am EST

BRIDGEWATER, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2020, on Thursday, November 5, 2020, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

Conference Call   
Thursday, November 5th @ 8:30am Eastern Time
Toll Free:  800-289-0438
International:  323-794-2423
Conference ID:  9576782
Webcast:  http://public.viavid.com/index.php?id=142196

A replay of the call will be archived on the Company’s website at https://vynetherapeutics.com promptly after the conference call.

About VYNE Therapeutics Inc.
VYNE Therapeutics’ mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.

With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for AMZEEQ® (minocycline) topical foam, 4%, the world’s first topical minocycline, and for ZILXI™ (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. For more information about our approved products, please see AMZEEQ’s Full Prescribing Information at amzeeq.com and ZILXI’s Full Prescribing Information at zilxi.com.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Media Relations:
Bridgette Potratz
Zeno Group
312-358-2950
bridgette.potratz@zenogroup.com

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
646-889-1200
jallaire@lifesciadvisors.com

Andrew Saik
Chief Financial Officer
VYNE Therapeutics
908-731-6180
Andrew.Saik@vynetx.com

 

Primary Logo


© GlobeNewswire 2020
All news about VYNE THERAPEUTICS INC.
01/22VYNE THERAPEUTICS : Announces Contract Execution for AMZEEQ and ZILXI with Major..
AQ
01/21VYNE THERAPEUTICS : Signs Deal With Pharmacy Benefit Manager for FDA-Approved Sk..
MT
01/21VYNE THERAPEUTICS : Announces Contract Execution for AMZEEQ® (minocycline) and Z..
AQ
01/07VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhi..
AQ
01/05VYNE THERAPEUTICS : to Present at the LifeSci Partners 10th Annual Healthcare Co..
AQ
2020VYNE THERAPEUTICS : Completes End-of-Phase 2 Meeting With FDA for FCD105 to Trea..
MT
2020VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for ..
GL
2020VYNE THERAPEUTICS : to Join Nasdaq Biotechnology Index
MT
2020VYNE THERAPEUTICS : Added to Nasdaq Biotechnology Index
AQ
2020VYNE THERAPEUTICS : Wins US Patent for Acne Treatment Amzeeq
MT
More news
Financials (USD)
Sales 2020 21,9 M - -
Net income 2020 -258 M - -
Net Debt 2020 - - -
P/E ratio 2020 -0,82x
Yield 2020 -
Capitalization 316 M 316 M -
Capi. / Sales 2020 14,4x
Capi. / Sales 2021 5,10x
Nbr of Employees 40
Free-Float -
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 5,93 $
Last Close Price 1,88 $
Spread / Highest target 432%
Spread / Average Target 215%
Spread / Lowest Target 59,6%
EPS Revisions